|Bid||85.49 x 800|
|Ask||88.19 x 1800|
|Day's Range||86.10 - 87.27|
|52 Week Range||73.69 - 89.09|
|PE Ratio (TTM)||81.20|
|Earnings Date||Jul 24, 2018|
|Forward Dividend & Yield||2.25 (2.63%)|
|1y Target Est||90.78|
Alder Biopharmaceuticals gapped up Friday after rival Teva Pharmaceutical scrapped a late-stage study in chronic cluster headaches.
Eli Lilly (LLY)/AstraZeneca (AZN) discontinue two late-stage studies on Alzheimer's disease candidate, lanabecestat. Merck's Keytruda gets FDA nod for two new indications.
Ricks says pharmacy benefit managers, or PBMs, are benefiting from price increases. "With the adoption of high-deductible plans, patients are subjected to the list price," said Ricks, who was in Minneapolis for the Piper Jaffray Heartland Summit, an annual health-care conference.
Eli Lilly and Company (NYSE:LLY) trades with a trailing P/E of 79.9x, which is higher than the industry average of 23.5x. While LLY might seem like a stock to avoidRead More...
Eli Lilly & Co said on Wednesday its drug to treat autoimmune disease lupus met the main goal of a mid-stage trial, positioning the drugmaker to begin a bigger study later this year. The data come two weeks after U.S. health regulators approved the drug, baricitinib, under the trade name Olumiant, with a far more restrictive label than expected to treat rheumatoid arthritis. There are few available treatments for lupus, which affects multiple organs and tissues in the body, causing symptoms that range from extreme fatigue and unexplained fever to joint pain and rash.
AstraZeneca PLC and Eli Lilly & Co. on Tuesday scrapped two late-stage trials of an experimental Alzheimer’s drug they were co-developing, the latest blow in the long quest to find a breakthrough for the memory-robbing disorder. The companies said the decision was taken after an independent data-monitoring committee concluded that trials associated with lanabecestat, the experimental drug, wouldn’t achieve their original goals. An AstraZeneca spokesman said the two will continue to jointly pursue an early-stage trial of another experimental Alzheimer’s drug.
have discontinued late-stage trials of their experimental Alzheimer's disease drug lanabecestat, sending both companies' stock prices down Tuesday. AstraZeneca's stock fell 22 cents to close at $36.16 a share, while Lilly dropped 35 cents to $85.49. "The complexity of Alzheimer's disease poses one of the most difficult medical challenges of our time, and we are deeply disappointed for the millions suffering from the devastating disease," Dr. Daniel Skovronsky, president of Lilly Research Labs, said in the statement.
AstraZeneca and Eli Lilly became the latest Tuesday in a series of firms to scrap studies of a potential Alzheimer's disease treatment that appeared unlikely to work.
An independent data monitoring committee concluded the new drug candidate would not meet the desired endpoint in two late-stage clinical trials.
Eli Lilly (LLY) and AstraZeneca (AZN) are discontinuing two late-stage studies on their Alzheimer's disease candidate, lanabecestat.
The discontinuation of Lilly/AstraZeneca's two late-stage studies on their Alzheimer's disease candidate, lanabecestat adds to a long list of failed treatment options for this deadly brain disease.
Eli Lilly and Co and AstraZeneca Plc said on Tuesday they would discontinue late-stage trials testing their Alzheimer's treatment, the latest among a slew of drugmakers to stop developing treatments for the memory-robbing disease. The treatment, lanabecestat, belongs to a class of drugs called beta secretase cleaving enzyme (BACE) inhibitor, that blocks an enzyme involved in the production of a protein that creates brain plaques, considered a major cause of the disease. Experimental Alzheimer's drugs have had a dismal track record, with more than 100 failures, with Johnson and Johnson last month stopping mid-stage trials testing its BACE inhibitor drug.
Eli Lilly & Co. and AstraZeneca Plc ended two late-stage trials of an experimental drug for Alzheimer’s disease after the treatment failed to show any signs of working, adding to a litany of disappointments for the memory-robbing illness. An independent data monitoring committee found that the medicine, lanabecestat, was unlikely to meet the goals of the studies, one for early Alzheimer’s and the other for mild dementia related to the disease, the companies said in a statement Tuesday. Many researchers now believe that administering drugs after amyloid has built up in the brain may come too late to affect Alzheimer’s progress.
INDIANAPOLIS, June 12, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) and AstraZeneca are discontinuing the global Phase 3 clinical trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibitor, for the treatment of Alzheimer's disease. The decision is based on recommendations by an independent data monitoring committee (IDMC) which concluded that both the AMARANTH trial, in early Alzheimer's disease, and the DAYBREAK-ALZ trial, in mild Alzheimer's disease dementia, were not likely to meet their primary endpoints upon completion and therefore should be stopped for futility. As a result of this decision, the related AMARANTH extension trial will also be discontinued.
AstraZeneca and Eli Lilly are to halt a global trial of a drug meant to treat people suffering from early and mild forms of Alzheimer’s disease after a panel found the treatment was unlikely to meet its ...
Typically, they would be held back by the gravitational pull of profit-takers and of the intrusion of higher rates or politics or weaker business. Price target boosting and research defenses and insurgents trying to make things happen. Let's go over all three starting with the target boost.
"Mad Money" host Jim Cramer breaks down President Trump's strategy on trade and why he has taken a hard stance with China. Cramer also reverses his stance on Jack Dorsey, the CEO of Twitter and Square. In the lightning round, Cramer warns against investing in a home security stock.
The recent action in Eli Lilly's stock speaks to how analysts are interpreting the market layout, "Mad Money" host Jim Cramer says. While markets were tepid on Monday ahead of a historic summit between the United States and North Korea, CNBC's Jim Cramer noticed a separate pattern taking hold on Wall Street. Cramer pointed to Eli Lilly LLY .
AstraZeneca's (AZN) Tagrisso gets an EU nod for first-line treatment of advanced or metastatic non-small cell lung cancer in patients with epidermal growth factor receptor (EGFR) mutations.